Cargando…
Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018
BACKGROUND: Type 2 diabetes mellitus (T2DM) greatly increases cardiovascular risk. Primary and secondary cardiovascular prevention lead to lower cardiovascular events, improved quality of life and lower costs related to complications. OBJECTIVE: To estimate the proportion of patients with T2DM under...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772352/ https://www.ncbi.nlm.nih.gov/pubmed/33787394 http://dx.doi.org/10.1177/21501327211007015 |
_version_ | 1784635829471150080 |
---|---|
author | Machado-Duque, Manuel E. Garcia, Diego Arturo Emura-Vélez, Melissa Hiromi Gaviria-Mendoza, Andrés Machado-Alba, Jorge E. |
author_facet | Machado-Duque, Manuel E. Garcia, Diego Arturo Emura-Vélez, Melissa Hiromi Gaviria-Mendoza, Andrés Machado-Alba, Jorge E. |
author_sort | Machado-Duque, Manuel E. |
collection | PubMed |
description | BACKGROUND: Type 2 diabetes mellitus (T2DM) greatly increases cardiovascular risk. Primary and secondary cardiovascular prevention lead to lower cardiovascular events, improved quality of life and lower costs related to complications. OBJECTIVE: To estimate the proportion of patients with T2DM undergoing drug therapy for cardiovascular prevention (aspirin and statins) in Colombia and to describe the change in patterns of use between 2008 and 2018. METHODS: This was a cross-sectional study comparing prescriptions for aspirin and statins in 2008 and in 2018 in outpatients diagnosed with T2DM. Records were obtained from a national drug claim database. The proportion of use of cardiovascular prevention drugs and antidiabetic drugs, medications for comorbidities and sociodemographic variables were analyzed for both periods. RESULTS: In total, 26 742 patients in 2008 and 188 321 in 2018 with a diagnosis of T2DM treated with antidiabetic drugs were identified, among whom 57.5% and 44.2% received aspirin and 44.9% and 60.2% received statins, respectively. The use of high-intensity statins increased from 1.1% in 2008 to 95.2% in 2018. The probabilities of receiving drugs in 2008 and in 2018 were higher for men (OR: 1.12, 95% CI: 1.06-1.17 and OR: 1.26, 95% CI: 1.23-1.28, respectively), for those persons over 75 years of age (OR: 6.5, 95% CI: 5.3-7.9 and OR: 5.8, 95% CI: 5.4-6.2) and for those who also received clopidogrel (OR: 5.8, 95% CI: 4.4-7.6 and OR: 2.2, 95% CI: 2.1-2.4). CONCLUSIONS: The use of high-intensity statins in patients with T2DM has increased significantly in the last decade, which should reduce cardiovascular events, morbidity and mortality. |
format | Online Article Text |
id | pubmed-8772352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-87723522022-01-21 Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018 Machado-Duque, Manuel E. Garcia, Diego Arturo Emura-Vélez, Melissa Hiromi Gaviria-Mendoza, Andrés Machado-Alba, Jorge E. J Prim Care Community Health Latin America Health: Public Policy and Primary Care BACKGROUND: Type 2 diabetes mellitus (T2DM) greatly increases cardiovascular risk. Primary and secondary cardiovascular prevention lead to lower cardiovascular events, improved quality of life and lower costs related to complications. OBJECTIVE: To estimate the proportion of patients with T2DM undergoing drug therapy for cardiovascular prevention (aspirin and statins) in Colombia and to describe the change in patterns of use between 2008 and 2018. METHODS: This was a cross-sectional study comparing prescriptions for aspirin and statins in 2008 and in 2018 in outpatients diagnosed with T2DM. Records were obtained from a national drug claim database. The proportion of use of cardiovascular prevention drugs and antidiabetic drugs, medications for comorbidities and sociodemographic variables were analyzed for both periods. RESULTS: In total, 26 742 patients in 2008 and 188 321 in 2018 with a diagnosis of T2DM treated with antidiabetic drugs were identified, among whom 57.5% and 44.2% received aspirin and 44.9% and 60.2% received statins, respectively. The use of high-intensity statins increased from 1.1% in 2008 to 95.2% in 2018. The probabilities of receiving drugs in 2008 and in 2018 were higher for men (OR: 1.12, 95% CI: 1.06-1.17 and OR: 1.26, 95% CI: 1.23-1.28, respectively), for those persons over 75 years of age (OR: 6.5, 95% CI: 5.3-7.9 and OR: 5.8, 95% CI: 5.4-6.2) and for those who also received clopidogrel (OR: 5.8, 95% CI: 4.4-7.6 and OR: 2.2, 95% CI: 2.1-2.4). CONCLUSIONS: The use of high-intensity statins in patients with T2DM has increased significantly in the last decade, which should reduce cardiovascular events, morbidity and mortality. SAGE Publications 2021-03-31 /pmc/articles/PMC8772352/ /pubmed/33787394 http://dx.doi.org/10.1177/21501327211007015 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Latin America Health: Public Policy and Primary Care Machado-Duque, Manuel E. Garcia, Diego Arturo Emura-Vélez, Melissa Hiromi Gaviria-Mendoza, Andrés Machado-Alba, Jorge E. Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018 |
title | Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018 |
title_full | Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018 |
title_fullStr | Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018 |
title_full_unstemmed | Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018 |
title_short | Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018 |
title_sort | prevalence of the use of aspirin and statins for preventing cardiovascular events in the colombian population with type 2 diabetes mellitus: comparison of 2008 and 2018 |
topic | Latin America Health: Public Policy and Primary Care |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772352/ https://www.ncbi.nlm.nih.gov/pubmed/33787394 http://dx.doi.org/10.1177/21501327211007015 |
work_keys_str_mv | AT machadoduquemanuele prevalenceoftheuseofaspirinandstatinsforpreventingcardiovasculareventsinthecolombianpopulationwithtype2diabetesmellituscomparisonof2008and2018 AT garciadiegoarturo prevalenceoftheuseofaspirinandstatinsforpreventingcardiovasculareventsinthecolombianpopulationwithtype2diabetesmellituscomparisonof2008and2018 AT emuravelezmelissahiromi prevalenceoftheuseofaspirinandstatinsforpreventingcardiovasculareventsinthecolombianpopulationwithtype2diabetesmellituscomparisonof2008and2018 AT gaviriamendozaandres prevalenceoftheuseofaspirinandstatinsforpreventingcardiovasculareventsinthecolombianpopulationwithtype2diabetesmellituscomparisonof2008and2018 AT machadoalbajorgee prevalenceoftheuseofaspirinandstatinsforpreventingcardiovasculareventsinthecolombianpopulationwithtype2diabetesmellituscomparisonof2008and2018 |